Skip to content
Screener

iRhythm Holdings, Inc. IRTC Financing Cash Flow

Financing Cash Flow at other companies

Baxter International logo
Baxter InternationalBAX
-$11M+99.7%
Boston Scientific logo
Boston ScientificBSX
-$260M-212%
Kestra Medical Technologies logo
Kestra Medical TechnologiesKMTS
$0-100%
Owlet logo
OwletOWLT
$5.46M+171%
CeriBell, Inc. logo
CeriBell, Inc.CBLL
$880K-56.1%
Medtronic logo
MedtronicMDT
-$888M+33.9%

Other financials

Income statement

See full
Revenue$224.2M+20.1%
Gross profit$163.2M+22.8%
Operating income-$2.5M+86.4%
Net income-$381.0K+97.3%
EPS (diluted)-$0.01+97.7%

Balance sheet

See full
Cash & equivalents$255.0M-19.7%
Total debt$76.3M-12.1%
Total equity$186.0M+79.4%
Total assets$1.1B+13.4%

Cash flow

See full
Operating cash flow$51.1M+84.7%
CapEx$13.6M+30.8%
Free cash flow$37.5M+117%

Valuation

See full
Market cap$4.2B-18.6%
Enterprise value$4.02B-18.4%
P/S5.1×-2.8×

Profitability

See full
Gross margin71.5%+1.7pp
Operating margin-3.3%-1.5pp
Net margin-7.3%-3.1pp
FCF margin4.7%

Returns & leverage

See full
Return on equity-53.1%-17.4pp
Debt / equity0.4×-0.4×
Current ratio3.9×-1.2×

Where this comes from

Reported directly by iRhythm Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: iRhythm Holdings, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001388658-26-000072
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Cash flows from financing activities
Proceeds from issuance of common stock in connection with employee equity incentive plans4,2328,823
Repayment of 2029 Notes(3)
Net cash provided by financing activities4,2298,823
Effect of exchange rate changes(46)(29)
Net increase (decrease) in cash, cash equivalents and restricted cash10,667(110,492)
Cash, cash equivalents and restricted cash, beginning of period244,370427,955
Cash, cash equivalents and restricted cash, end of period$255,037$317,463

Item 1. Financial Statements (Unaudited):

FAQ

What is iRhythm Holdings, Inc.'s financing cash flow?
iRhythm Holdings, Inc. (IRTC) reported financing cash flow of $4.08M in Q2 2026.
How has iRhythm Holdings, Inc.'s financing cash flow changed year-over-year?
iRhythm Holdings, Inc.'s financing cash flow decreased by 42.5% year-over-year, from $7.09M to $4.08M.
What is the long-term trend for iRhythm Holdings, Inc.'s financing cash flow?
Over 3 years (2022 to 2025), iRhythm Holdings, Inc.'s financing cash flow has grown at a -22.1% compound annual growth rate (CAGR), from $26.72M to $12.61M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about iRhythm Holdings, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude